1. Home
  2. ADMA vs ALKS Comparison

ADMA vs ALKS Comparison

Compare ADMA & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADMA
  • ALKS
  • Stock Information
  • Founded
  • ADMA 2004
  • ALKS 1987
  • Country
  • ADMA United States
  • ALKS Ireland
  • Employees
  • ADMA N/A
  • ALKS N/A
  • Industry
  • ADMA Biotechnology: Biological Products (No Diagnostic Substances)
  • ALKS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ADMA Health Care
  • ALKS Health Care
  • Exchange
  • ADMA Nasdaq
  • ALKS Nasdaq
  • Market Cap
  • ADMA 5.1B
  • ALKS 5.1B
  • IPO Year
  • ADMA N/A
  • ALKS 1991
  • Fundamental
  • Price
  • ADMA $17.74
  • ALKS $29.09
  • Analyst Decision
  • ADMA Strong Buy
  • ALKS Buy
  • Analyst Count
  • ADMA 4
  • ALKS 12
  • Target Price
  • ADMA $24.25
  • ALKS $40.00
  • AVG Volume (30 Days)
  • ADMA 2.7M
  • ALKS 1.6M
  • Earning Date
  • ADMA 08-07-2025
  • ALKS 07-23-2025
  • Dividend Yield
  • ADMA N/A
  • ALKS N/A
  • EPS Growth
  • ADMA N/A
  • ALKS N/A
  • EPS
  • ADMA 0.84
  • ALKS 2.09
  • Revenue
  • ADMA $459,381,000.00
  • ALKS $1,513,770,000.00
  • Revenue This Year
  • ADMA $23.35
  • ALKS N/A
  • Revenue Next Year
  • ADMA $27.67
  • ALKS $4.25
  • P/E Ratio
  • ADMA $21.27
  • ALKS $13.92
  • Revenue Growth
  • ADMA 62.23
  • ALKS N/A
  • 52 Week Low
  • ADMA $10.21
  • ALKS $22.90
  • 52 Week High
  • ADMA $25.67
  • ALKS $36.45
  • Technical
  • Relative Strength Index (RSI)
  • ADMA 32.83
  • ALKS 38.82
  • Support Level
  • ADMA $20.42
  • ALKS $29.26
  • Resistance Level
  • ADMA $22.37
  • ALKS $30.52
  • Average True Range (ATR)
  • ADMA 0.88
  • ALKS 0.78
  • MACD
  • ADMA -0.28
  • ALKS -0.24
  • Stochastic Oscillator
  • ADMA 1.07
  • ALKS 4.96

About ADMA ADMA Biologics Inc

ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.

About ALKS Alkermes plc

Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Share on Social Networks: